Published in TB and Outbreaks Week, November 6th, 1995
Confusion about how best to use currently approved anti-HIV drugs is a direct result of a focus on the dosage, rather than the dynamics, of experimental drugs, early in the clinical trial process, according to Michael N. Dudley of Roger Williams Medical Center, Providence, Rhode Island.
Dudley spoke during a symposium held at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held September 17-20 in San Francisco,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.